



SERIES- 28

NOVEMBER- 2021



Compiled & Edited by

**Department of
Pharmacology
KMCHIHSR
Coimbatore - 641014**

INSIDE THE SERIES

1. Avacopan
2. Allogeneic processed thymus tissue-agdc
3. Varenicline
4. Celecoxib and tramadol hydrochloride
5. Naloxone hydrochloride
6. Triamcinolone acetonide
7. Ranibizumab
8. Pilocarpine hydrochloride
9. Asciminib

We're on the Web!

www.kmchihsr.edu.in

Mail us:

hodpharmacology@kmchihsr.edu.in

1. Avacopan

Approval date: October 07, 2021

Mechanism of action: It is a specific C5aR receptor allosteric antagonist that inhibits C5a-mediated neutrophil activation

Indication: Adjunctive treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis

Dosage formulation: Capsule

2. Allogeneic processed thymus tissue-agdc

Approval date: October 08, 2021

Indication: one-time regenerative tissue-based therapy indicated for immune reconstitution in pediatric patients with congenital athymia

Dosage formulation: Surgical implant (yellow to brown slices of allogeneic processed thymus tissue)

3. Varenicline

Approval date: October 15, 2021

Mechanism of action: alpha-4 beta-2 neuronal nicotinic acetylcholine receptor partial agonist, inhibits the ability of nicotine to bind to and activate the alpha-4 beta-2 receptor

Indication: Treatment of the signs and symptoms of dry eye disease

Dosage formulation: Nasal Spray

4. Celecoxib and tramadol hydrochloride

Approval date: October 15, 2021

Mechanism of action: Celecoxib - Inhibits cyclooxygenase (COX)-2, thereby decreasing formation of prostaglandin synthesis. Tramadol - Nonopioid-derived synthetic opioid, binding to opioid mu receptors, causing inhibition of ascending pain pathways

Indication: Indicated for the management of acute pain in adults that requires opioid analgesic

Dosage formulation: Tablet

5. Naloxone hydrochloride

Approval date: October 15, 2021

Mechanism of action: Competitive inhibitor of the μ -opioid receptor

Indication: Treatment of opioid overdose

Dosage formulation: Injection – IM/SC (Single, Prefilled, high-dose formulation)

6. Triamcinolone acetonide

Approval date: October 22, 2021

Mechanism of action: Inhibit phospholipase A2 on cell membranes

Indication: Treatment of macular edema associated with uveitis

Dosage formulation: Injection (suprachoroidal injectable suspension)

7. Ranibizumab

Approval date: **October 25, 2021**

Mechanism of action: Vascular endothelial growth factor (VEGF) inhibitor

Indication: Treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who has previously responded to at least two intravitreal injections of a VEGF inhibitor.

Dosage formulation: **Injection** (Intravitreal Use via Ocular Implant)

8. Pilocarpine Hydrochloride

Approval date: **October 28, 2021**

Mechanism of action: Cholinergic muscarinic receptor agonist

Indication: Treatment of presbyopia (age-related blurry near vision)

Dosage formulation: **Ophthalmic solution**

9. Asciminib

Approval date: **October 29, 2021**

Mechanism of action: Tyrosine kinase inhibitor

Indication: Treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)

Dosage formulation: **Tablet**